CompletedPhase 2

Suvorexant for Opioid/Stimulant Co-use

United States20 participantsStarted 2022-12-01

Plain-language summary

This study will evaluate whether Suvorexant 20mg reduces drug use and craving, and improves sleep and stress among persons with co-occurring opioid use disorder and stimulant use disorder.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Ages 18-65,
✓. Meet criteria for stimulant use disorder, based on the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR)
✓. Currently receiving methadone or buprenorphine treatment for OUD and considered to be stable on current dose for at least 30 days
✓. Willingness to engage with study protocol
✓. Use of birth control (as appropriate)

Exclusion criteria

✕. Psychiatric or medical conditions that are judged by the investigators to interfere with participation or that are contraindicated for use with SUVO
✕. Pregnant or breastfeeding
✕. Current use of benzodiazepines, tranquilizers, or other schedule IV sleep medications
✕. Moderate or severe substance use disorder other than opioid or stimulant use disorder
✕. SUVO consumption in the last 30 days
✕. Use of medications that are contraindicated with the study
✕. Past 30-day suicidal behavior
✕. Use of continuous positive airway pressure (CPAP) device for sleep apnea

What they're measuring

Opioid Use: Proportion of Positive Urine Drug Screens (UDS)

Timeframe: Up to 30 days post-randomization

Cocaine Use: Proportion of Positive UDS Screens

Timeframe: Up to 30 days post-randomization

Trial details

NCT IDNCT05546515

SponsorJohns Hopkins University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-11-30

Results submitted2025-11-24

View on ClinicalTrials.gov More Opioid Use Disorder trials